1. Home
  2. FMN vs IMUX Comparison

FMN vs IMUX Comparison

Compare FMN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Federated Hermes Premier Municipal Income Fund

FMN

Federated Hermes Premier Municipal Income Fund

N/A

Current Price

$11.19

Market Cap

87.8M

Sector

Finance

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

N/A

Current Price

$1.26

Market Cap

75.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FMN
IMUX
Founded
2002
2016
Country
United States
United States
Employees
N/A
66
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.8M
75.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
FMN
IMUX
Price
$11.19
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$4.25
AVG Volume (30 Days)
28.2K
4.9M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.86%
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.11
$0.51
52 Week High
$11.38
$1.35

Technical Indicators

Market Signals
Indicator
FMN
IMUX
Relative Strength Index (RSI) 39.24 74.69
Support Level $10.98 $0.61
Resistance Level $11.29 N/A
Average True Range (ATR) 0.11 0.10
MACD -0.02 0.03
Stochastic Oscillator 57.78 93.20

Price Performance

Historical Comparison
FMN
IMUX

About FMN Federated Hermes Premier Municipal Income Fund

Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: